| Product | Developer | Development stage at time of guidance |
|---|
Product | Developer | Development stage at time of guidance |
|---|---|---|
| ABNCoV2 | Bavarian Nordic AS | Clinical phase |
| Ad26.COV2.S | Janssen-Cilag International N.V. | Non-clinical phase |
| Ad5-nCoV vaccine | Cansino Biotech | Clinical phase |
| Ad5-nCoV-IH | Cansino Biotech | Clinical phase |
| Adjuvanted whole virion inactivated vaccine | Sinovac Life Sciences Co | Non-clinical phase |
| ARCT-154 | Arcturus Therapeutics Europe B.V. | Clinical phase |
| CD40.RBDv, CD40.Pan.CoV | LinKinVax | Non-clinical phase |
| ChAdOx1-SARS-CoV-2 | Vaccitech/AstraZeneca | Clinical phase |
| Coronavirus-like particle (COVLP) | Medicago | Non-clinical phase |
| COVI-Liv | Bilthoven Biologicals B.V. | Clinical phase |
| CV0501 | CureVac and GSK | Clinical phase |
| CVnCoV, CV07050101 vaccine | Curevac | Non-clinical phase |
| Dellera, mRNA vaccine | Fondo Ricerca Medica S.r.l. | Clinical phase |
| DNA Plasmid vaccine | Takis S.r.l., Rottapham Biotech | Non-clinical phase |
| FINCoVac 2.0 vaccine | Rokote Laboratories Finland Oy | Non-clinical phase |
| Gam-COVID-Vac | The Gamaleya National Centre of Epidemiology and Microbiology | Clinical phase |
| GBP510 | Sk Bioscience Co. Ltd | Clinical phase |
| GRAd-COV2 | Reithera S.r.l. | Clinical phase |
| GSK&CV SARS-COV-2 vaccine (2nd generation) | GSK and CureVac | Clinical phase |
| Herpes simplex virus vector tetravalent SARS-CoV-2 vaccine | Krystal Bio | Non-clinical phase |
| INO-4800 | Inovio | Clinical phase |
| ISR52 | ISR Vaccine AB | Non-clinical phase |
| LNP-saRNA CoVid19 vaccine | VacEquity Global Health/Imperial College London | Clinical phase |
| LUNAR-COV19 mRNA vaccine | Arcturus Therapeutics | Clinical phase |
| mRNA SARS-CoV-2 vaccine | Biontech | Non-clinical phase |
| Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
|---|
Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
|---|---|---|---|
| 2-DEOXY-D-GLUCOSE | Dermin Sp. Z.0.0 | Other therapeutic | Non-clinical Phase Clinical phase |
| 4P021 | 4P-Pharma | Antiviral | Non-clinical phase |
| A64-DP | BCN Peptides SA | Immunomodulator | Non-clinical phase |
| ABBV-47D11 | AbbVie | Antiviral | Clinical phase |
| Acalabrutinib | Acerta Pharma BV / AstraZeneca | Immunomodulator | Clinical phase |
| ADG20 | Adagio Therapeutics | Immunomodulator | Clinical phase |
| ALG-097558 | Aligos Belgium BV | Antiviral | Non-clinical phase |
| Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin | Alliance hyperimmune project (Biotest AG, Bio Products Laboratory, LFB, Octapharma, CSL Behring and Takeda) | Antiviral | Clinical phase |
| APN01 | Apeiron Biologics | Immunomodulator | Clinical phase |
| Apremilast | Amgen Europe BV | Immunomodulator | Clinical phase |
| Aprotinin | Gerencia De Atención Integrada De Ciudad Real | Antiviral | Clinical phase |
| AR-711 | Aridis Pharmaceuticals, Inc. | Antiviral (monoclonal antibody) | Non-clinical phase |
| Arylacenamide | Meletios Therapeutics | Antiviral and immunomodulator | Clinical phase |
| ASUNERCEPT | Apogenix AG | Immunomodulator | Clinical phase |
| AT-527 | Roche | Antiviral | Clinical phase |
| Aviptadil | Relief Therapeutics Holding S.A | Other therapeutic | Clinical phase |
| AZD7442 | AstraZeneca | Antiviral (monoclonal antibody) | Non-clinical phase |
| AZD7518 (AZD3152, AZD3959) | AstraZeneca AB | Antiviral (monoclonal antibody) | Clinical phase |
| Azelastine | Ursapharm | Immunomodulator | Clinical phase |
| Baricitinib | Eli Lilly | Immunomodulator | Clinical phase |
| BC 007 (GS 522 or ARC183) | Berlin Cures | Immunomodulator | Clinical phase |
| Bemcentinib | BergenBio | Antiviral | Clinical phase |
| Bemnifosbuvir hemisulfate | Atea Pharmaceuticals Inc | Antiviral | Clinical phase |
| BI 764198 | Boehringer Ingelheim International GmbH | Other therapeutic | Clinical phase |
| BMS986414 and BMS986413 | Rockefeller University and Bristol Myers Squibb | Antiviral (monoclonal antibody) | Clinical phase |
Reply to the European Ombudsman’s letter concerning transparency and independence of the work of the European Medicines Agency in supporting the development and evaluation of COVID-19 medicines
English (EN) (192.91 KB - PDF)